Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This phase I study studies the side effects and best dose of venetoclax and lenalidomide when
given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that
has returned after a period of improvement or not responding to treatment. Monoclonal
antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and
spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may
work better in treating patients with B-cell non-Hodgkin lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Beth Christian
Collaborators:
Celgene Genentech, Inc. National Cancer Institute (NCI)